BioLingus (Cayman) Limited (SUBL)

SUBL Balance Sheet

Financials in millions USD. Fiscal year is May - April.

Year	2022	2021
Cash & Equivalents	0.16	0.11
Short-Term Investments	0.04	0.13
Cash & Cash Equivalents	0.2	0.24
Cash Growth	-17.19%	-
Other Current Assets	0.07	0.14
Total Current Assets	0.27	0.38
Goodwill and Intangibles	0.09	0.37
Total Long-Term Assets	0.09	0.37
Total Assets	0.36	0.74
Accounts Payable	0.5	0.84
Current Debt	5.02	2.83
Other Current Liabilities	0	1
Total Current Liabilities	5.53	4.67
Long-Term Debt	1.6	2.45
Other Long-Term Liabilities	0.89	0
Total Long-Term Liabilities	2.49	2.45
Total Liabilities	8.02	7.11
Total Debt	6.63	5.27
Debt Growth	25.65%	-
Retained Earnings	-7.75	-6.33
Comprehensive Income	0.09	-0.04
Shareholders' Equity	-7.66	-6.37
Net Cash / Debt	-6.43	-5.03
Working Capital	-5.26	-4.29

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).